4月1日，歌礼制药-B（01672）股价盘中大涨5.20%，引起市场广泛关注。截至盘中，该股报价为【具体价格】港元。
消息面上，歌礼制药于3月31日宣布，其肥胖症新药ASC30在美国进行的Ib期临床试验取得积极的期中结果。这项随机、双盲、安慰剂对照的研究针对体重指数在30-40 kg/m²之间的肥胖症患者，评估了含有小分子ASC30的三种超长效皮下注射制剂。
值得注意的是，ASC30被歌礼制药称为首款也是唯一一款既可每日一次口服，也可每月一次或更低频率皮下注射的用于治疗肥胖症的试验阶段小分子GLP-1R激动剂。这一独特的给药方式可能为患者提供更多选择，有望提高治疗的依从性。该积极的临床试验结果显示了ASC30在肥胖症治疗领域的潜力，这可能是推动歌礼制药-B股价上涨的主要原因。随着全球肥胖问题日益严重，市场对有效的肥胖症治疗药物需求也在不断增加，投资者对歌礼制药在这一领域的进展表示乐观。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.